These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12471654)

  • 1. [ASSENT III and GUSTO V: is it the end of combination therapy with GPIIb/IIIa blockers and thrombolytics in myocardial infarction?].
    Vahanian A
    Ann Cardiol Angeiol (Paris); 2002 Jan; 51(1):6-7. PubMed ID: 12471654
    [No Abstract]   [Full Text] [Related]  

  • 2. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
    Nordt TK; Peter K; Bode C
    Herz; 2001 Apr; 26 Suppl 1():42-5. PubMed ID: 11349626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials.
    Califf RM
    Am Heart J; 1999 Jul; 138(1 Pt 2):S12-5. PubMed ID: 10385786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of acute coronary syndromes.
    Schulman SP; Fessler HE
    Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971
    [No Abstract]   [Full Text] [Related]  

  • 9. Too much, too little, or none at all: dealing with substandard and fake drugs.
    Wan Po AL
    Lancet; 2001 Jun; 357(9272):1904. PubMed ID: 11425409
    [No Abstract]   [Full Text] [Related]  

  • 10. Confusion in reperfusion.
    Gibson CM
    J Am Coll Cardiol; 2003 Oct; 42(7):1186-7. PubMed ID: 14522477
    [No Abstract]   [Full Text] [Related]  

  • 11. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
    Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
    Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Roe MT; Sapp SK; Lincoff AM
    Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
    Simoons ML;
    Lancet; 2001 Jun; 357(9272):1915-24. PubMed ID: 11425411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
    Chew DP; Moliterno DJ
    Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
    Dubois CL; Belmans A; Granger CB; Armstrong PW; Wallentin L; Fioretti PM; López-Sendón JL; Verheugt FW; Meyer J; Van de Werf F;
    J Am Coll Cardiol; 2003 Oct; 42(7):1178-85. PubMed ID: 14522476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
    Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.